
NASDAQHealthcareMedical - Devices
最新資料
US$7.97
−US$0.18 · -2.21%
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
收盤時
US$7.97
−US$0.18 · -2.21%
盤後
US$7.47
−US$0.50 · -6.27%
10月13日 下午4:08 ET
盤中時間採用ET。市場資料可能有所延遲。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日內區間
目前US$7.97
52週區間
目前US$7.97
盤中時間採用ET。市場資料可能有所延遲。
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.
日內區間
目前US$7.97
52週區間
目前US$7.97
營業利益
淨利
| 項目(USD) | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | 52.8萬 USD | 54.6萬 USD | 52.5萬 USD | 45.29萬 USD |
| 毛利 | — | −52.8萬 USD | −54.6萬 USD | −52.5萬 USD | −45.29萬 USD |
| 研究與開發 | 998.1萬 USD | 1224.9萬 USD | 1358.3萬 USD | 991.4萬 USD | 572.76萬 USD |
| 銷售、一般及管理費用 | 1091.8萬 USD | 1104.9萬 USD | 1110.9萬 USD | 1449.3萬 USD | 1071.19萬 USD |
| 營業費用 | 2089.9萬 USD | 2329.8萬 USD | 2469.2萬 USD | 2440.7萬 USD | 1643.96萬 USD |
| 利息收入 | 69.2萬 USD | 38.9萬 USD | 18萬 USD | 16.1萬 USD | 1.87萬 USD |
| 折舊和攤銷 | 48.9萬 USD | 52.8萬 USD | 54.6萬 USD | 52.5萬 USD | 45.3萬 USD |
| 營業利益 | −2089.9萬 USD | −2382.6萬 USD | −2523.8萬 USD | −2493.2萬 USD | −1689.25萬 USD |
| 淨利 | −1947.2萬 USD | −2181.9萬 USD | −2351.6萬 USD | −2466.9萬 USD | −1652.78萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2026年1月20日 | 1:35 | — | — |
股票分割 | 2020年11月30日 | 1:25 | — | — |
已生效 2026年1月20日
1:35
已生效 2020年11月30日
1:25
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途,不構成投資建議。